Program
TQA3038
A development code. Also written as “TQA3038 injection”.
In Sino Biopharmaceutical's pipeline, siRNA
. Its studies are mostly in Hepatitis B, Chronic, led by Sino Biopharmaceutical.
Furthest: phase 1, since Oct 11, 20231 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 1since Oct 11, 2023 | Oct 11, 2023 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQA3038
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2023First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT06085053 · 54 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“siRNA”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06085053Hepatitis B, Chronic · China | 1 | Recruiting | Dec 2024 | 54 |
How it is read
Names in the registry
- “TQA3038 injection”, 1 entry
Codes read as this program: TQA3038.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.